Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Phase 1TerminatedNCT00460460

AstraZeneca75 enrolled

Overview

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experienced by patients that receive AZD4877 on a weekly basis in these diseases.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma

Interventions

AZD4877DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with AML, a certain type of ALL, NHL and MM * certain types of cancer of the lymph nodes * certain types of leukemias (blood cancers) * disease has or will fail with other treatments * relatively good overall health other than your cancer Exclusion Criteria: * poor bone marrow function (not producing enough blood cells) * serious heart conditions * poor liver or kidney function

Locations (3)

Research site

Buffalo, New York, United States

Research Site

New York, New York, United States

Research Site

Toronto, Ontario, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.